Empagliflozin in Heart Failure with a Preserved Ejection Fraction

New Engl J Med.

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.